On May 26, 2022 Caris Life Sciences(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare reported that the company and partners within its Precision Oncology Alliance (POA) will collectively present 45 studies across more than 20 various solid tumor types at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting from June 3-7, 2022 (Booth #22081) (Press release, Caris Life Sciences, MAY 26, 2022, View Source [SID1234615142]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The breadth of research being presented at ASCO (Free ASCO Whitepaper) illustrates the power of comprehensive molecular profiling and large-scale collaboration between more than 60 sites to address some of the biggest challenges in cancer care and precision oncology today," said Chadi Nabhan, M.D., MBA, FACP, Chairman of the Caris Precision Oncology Alliance. "The findings of these studies could help improve outcomes for patients with difficult-to-treat cancers and pioneer new approaches to care across diverse tumor types and patient populations."

"At Caris, our goal is to enable clinicians to make the best treatment choices, researchers to discover new targets, and the biopharmaceutical industry to develop the next breakthrough medicines," said David Spetzler, M.S., Ph.D., MBA, President and Chief Scientific Officer of Caris. "These presentations show how our scientists and partners in the POA are using Caris’ unique AI-driven platform – which combines data from DNA (Whole Exome), RNA (Whole Transcriptome), and protein profiling with real-world clinical evidence from over 378,000 lifetime cases – to unravel the complexities of cancer. Ultimately, these discoveries could advance personalized cancer care and improve outcomes for many patients."

The Caris Precision Oncology Alliance includes 65 cancer centers and academic institutions in the United States and beyond. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic data available through Caris molecular profiling, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker directed trials sponsored by biopharma. Additionally, as a member of the POA, institutions have access to Caris CODEai, the most comprehensive data solution in the industry with cancer treatment information and real-world clinical outcomes evidence for over 275,000 patients covering over 1 million data points per patient.

Three oral discussions focus on difficult to treat tumors and aggressive tumor types with low survival rates:

Comprehensive Genomic and Transcriptomic Characterization of Small Bowel Adenocarcinoma (Poster Number: 6)
June 4, 2022, 1:15-2:45 PM CDT

Biological and prognostic relevance of epigenetic regulatory genes in high-grade gliomas (HGGs) (Poster Number: 3570)
June 5, 2022, 11:30 AM-1:00 PM CDT

Surfaceome profiling revealed unique therapeutic vulnerabilities in transcriptional subtypes of small cell lung cancer (SCLC) (Poster Number: 142)
June 6, 2022, 11:30 AM-1:00 PM CDT
Other notable studies among the 45 accepted abstracts focus on key topics in oncology such as the tumor microenvironment, mechanisms of therapeutic resistance and rare biomarkers:

The tumor microenvironment and immune infiltration landscape of KRAS mutant pancreatic ductal adenocarcinomas (PDAC) compared to colorectal adenocarcinomas (CRC) (Poster Number: 127)
June 4, 2022, 8:00-11:00 AM CDT

Claudin 18 (CLDN18) gene expression and related molecular profile in gastric cancer (GC) (Poster Number: 36)
June 4, 2022, 8:00-11:00 AM CDT

The differential response to immune checkpoint inhibitors in colorectal and endometrial cancer patients according to different mismatch repair alterations (Poster Number: 418)
June 4, 2022, 8:00-11:00 AM CDT

Characterization of TIM3 and its ligands in colorectal cancer (Poster Number: 341)
June 4, 2022, 8:00-11:00 AM CDT

Exploring the nuances between BRCA1 and 2: a multiomic analysis (Poster Number: 456)
June 4, 2022, 1:15-4:15 PM CDT

S1314 Correlative analysis of ATM, RB1, ERCC2 and FANCC mutations and pathologic complete response (pT0) at cystectomy after neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC): implications for bladder preservation (Poster Number: 72)
June 4, 2022, 1:15-4:15 PM CDT

Reversion mutations in BRCA1 or BRCA2 genes: Resistant mechanism(s) in patients treated with platinum-based agents or poly (ADP-ribose) polymerase (PARP) inhibitors (Poster Number: 124)
June 5, 2022, 8:00-11:00 AM CDT

Characterization of MET exon 14 skipping alterations (METex14) in non–small cell lung cancer (NSCLC) using whole transcriptome sequencing (WTS) (Poster Number: 108)
June 6, 2022, 8:00-11:00 AM CDT
Poster and abstract summaries highlighting this research will be available onsite at Caris’ booth 22081. The full abstracts will be available through the official ASCO (Free ASCO Whitepaper) website on May 26.

On May 26, 2022 Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, reported that two presentations including findings of its lead candidate, CT-0508, accepted for presentation at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting taking place in Chicago, June 3-7 (Press release, Carisma Therapeutics, MAY 26, 2022, View Source [SID1234615141]). The company will present the latest data from its landmark CT-0508 chimeric antigen receptor macrophage (CAR-M) trial for patients with advanced metastatic HER2 overexpressing solid tumors, reaffirming safety and feasibility of its proprietary engineered cell therapy platform. Clinical trial design for phase 1 study of adenovirally transduced autologous macrophages, a second CT-0508 study, was also accepted for presentation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In the abstract "A Phase 1, first-in-human (FIH) study of the anti-HER2 CAR Macrophage CT-0508 in subjects with HER2 overexpressing solid tumors," Kim A. Reiss, MD, principal investigator of the Phase 1 clinical trial and an Assistant Professor of Hematology-Oncology at the Perelman School of Medicine at the University of Pennsylvania (Penn), will present an update on the ongoing clinical trial. The findings are the first clinical data of genetically engineered macrophages in humans and demonstrate that CT-0508 was well tolerated after infusion and there were no dose-limiting toxicities reported to date in the current study. CT-0508 was also successfully manufactured using macrophages obtained from heavily pre-treated, advanced solid tumor patients and showed high chimeric antigen receptor (CAR) expression, viability, and purity. The data provide the first clinical demonstration of the CAR-M mechanism of action, exhibiting tumor infiltration, remodeling of the solid tumor microenvironment, and early indications of T-cell activation.

"This additional patient data reinforces the potential of the CAR-M platform, which may have applicability across other therapeutic areas in addition to HER2 over expressing cancers," said Debora Barton, MD, Chief Medical Officer at Carisma Therapeutics. "We look forward to continuing the CT-0508 clinical trial to further observe how our CAR-M therapy can potentially address the unmet needs of patients with hard-to-treat cancers."

Also accepted for presentation at the ASCO (Free ASCO Whitepaper) Annual Meeting is, "A phase 1, first-in-human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors," overview of the design of the Phase 1 clinical trial, also presented by Dr. Reiss.

Both of the abstracts will be presented at the 2022 ASCO (Free ASCO Whitepaper) Annual Meeting in the "Developmental Therapeutics—Immunotherapy" poster session on June 5.

Editor’s Note: Carisma has licensed certain Penn-owned intellectual property from the University of Pennsylvania, and Penn’s Perelman School of Medicine receives sponsored research and clinical trial funding from the company. Penn may also be entitled to receive additional financial benefits from technologies licensed and optioned to Carisma in the future. In addition, Penn is a co-founder of the company and holds equity interests in Carisma.

About CT-0508
CT-0508 is a human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M). It is being evaluated in a landmark Phase 1 multi-center clinical trial that focuses on patients with recurrent or metastatic HER2-overexpressing solid tumors whose cancers do not have approved HER2-targeted therapies or who do not respond to treatment. We are selecting participants who have tumors of any anatomical origin, but with the commonality of overexpressing the HER2 receptor on the cell surface, which is the target for our CAR-M. The Phase 1 clinical trial is first-of-its-kind, marking the first time that engineered macrophages are being studied in humans. The trial continues to enroll patients at five U.S. sites, including Penn; the University of North Carolina Lineberger Comprehensive Cancer Center in Chapel Hill; City of Hope in Duarte, California; University of Texas MD Anderson Cancer Center in Houston, Texas; and Sarah Cannon Research Institute at Tennessee Oncology – Nashville.

On May 26, 2022 Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health reported that it will present intriguing data from their innovative cancer clinical research program at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, to be held both in person in Chicago and online from June 3-7 (Press release, Rutgers Cancer Institute of New Jersey, MAY 26, 2022, View Source [SID1234615140]). A total of 14 presentations, including 13 abstracts and one education session, have been accepted, highlighting research advances in several types of cancer, including leukemia, lymphoma, lung cancer and colorectal cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our passionate team of dedicated, globally recognized physicians and translational researchers is at the vanguard of transforming cancer management, working to develop new treatments, enhance patient care and professional support, and most importantly improve patient outcomes for the multitude of cancers we diagnose and treat," said Andrew M. Evens, DO, MSc, FACP, Associate Director, Clinical Services, Rutgers Cancer Institute; and System Director, Medical Oncology and Oncology Lead, Combined Medical Group, RWJBarnabas Health. "The high-powered lineup of valuable data to be unveiled at this year’s ASCO (Free ASCO Whitepaper) Annual Meeting reflects the command of medicine, technical expertise and leading-edge thinking that are the hallmarks of our cancer research program. The presentations will include significant findings on a number of key cancer treatment strategies, including the use of combination therapies for difficult-to-treat cancers, as well as the impact of social media on the emotional health of oncology professionals," added Dr. Evens, who is also Associate Vice Chancellor, Clinical Innovation and Data Analytics, Rutgers Biomedical and Health Sciences.

Highlights of the accepted abstracts include the following:

Results of an electronic survey of SWOG Cancer Research Network and Children’s Oncology Group members designed to assess the impact of social media on the emotional health and burnout of pediatric and adult oncology professionals. While social media engagement is common in oncology for patients and support groups to advance education and support, the impact on oncology professionals is unknown. The purpose of this survey, developed and piloted by adult and pediatric oncologists, was to evaluate professional social media use and its potential associations with wellness and burnout.
In an updated analysis of ECHELON-1, researchers studied overall survival of first-line brentuximab vedotin plus chemotherapy in patients with stage III/IV classical Hodgkin lymphoma. To date, an overall survival benefit has rarely been shown in first-line classical Hodgkin lymphoma (cHL) and a meaningful improvement in overall survival without the need for escalation of therapy or use of bleomycin would represent a significant advance in optimizing outcomes for these patients.
Initial findings of the phase 2, open-label DELPHINUS study of daratumumab in pediatric and young adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL). While current treatments provide a promising prognosis for pediatric ALL and LL, up to 25% of patients will be refractory to or relapse after frontline treatment. This trial seeks to determine the efficacy and safety of daratumumab, a human monoclonal antibody approved to treat multiple myeloma, when used in combination with standard chemotherapy in this patient population.
Updated data from the dose escalation part of a phase 1b, multicenter study of subasumstat in combination with pembrolizumab in patients with relapsed/refractory, checkpoint inhibitor (CPI)-exposed, non-squamous non-small-cell lung cancer or microsatellite-stable colorectal cancer. SUMOylation is a post-translational modification with a role in limiting type 1 interferon (IFN-1)-dependent immune responses. Subasumstat is a small-molecule inhibitor of SUMOylation with the potential to increase antitumor immunity and overcome tumor resistance to CPI by inducing IFN-1 signaling. Preclinical data suggest that subasumstat enhances antigen cross-presentation, promoting T cell dependent antitumor responses; subasumstat plus an anti-PD-1 CPI has shown synergistic tumor growth inhibition and activation of CD8+ T cells and natural killer cells in synergistic mouse models.

On May 26, 2022 Biotheryx, Inc., a clinical stage company discovering and developing a portfolio of innovative small molecule targeted protein degraders (TPDs) in areas of high unmet medical need, reported that its abstract highlighting supportive preclinical data for its lead asset BTX-1188, a potentially first-in-class, dual protein degrader of GSPT1 and IKZF1/3, will be presented in a poster at the 2022 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting taking place June 3-7, 2022, in Chicago, Illinois and virtually (Press release, BioTheryX, MAY 26, 2022, View Source [SID1234615139]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our distinctive PRODEGY platform is designed to enable the discovery and development of a broad range of targeted protein degrader molecules and BTX-1188 is the first of our pipeline to enter the clinic," said Leah Fung, Ph.D., Chief Scientific Officer of Biotheryx. "BTX-1188 is a molecular glue that was rationally designed to degrade GSPT1 and IKZF1/3. The data being presented at ASCO (Free ASCO Whitepaper) 2022 support the ongoing Phase 1 clinical trial evaluating BTX-1188 in patients with hematologic and solid tumor cancers and demonstrate what we believe to be our ability to design first-in-class molecular glues with the potential to improve clinical outcomes for patients with cancer and other serious diseases."

"We are leveraging our deep expertise with the modulation of Cereblon, the only clinically and commercially validated E3 ligase, to design innovative targeted protein degraders with the potential to address significant unmet medical need," said Philippe Drouet, President and Chief Executive Officer of Biotheryx. "We look forward to presenting these pre-clinical data from our lead program, BTX-1188, at ASCO (Free ASCO Whitepaper) 2022."

Key Highlights from BTX-1188 Preclinical Results

BTX-1188 has shown deep and durable degradation of GSPT1 and IKZF1/3 and inhibition of MYC in several types of hematologic and solid tumor cell lines, including lymphoma, diffuse large B-cell lymphoma, non-small cell lung cancer and glioma.
BTX-1188 has shown inhibition of pro-inflammatory cytokines and enhancement of immune stimulatory cytokines, owing to IKZF1/3 degradation, which may prevent the known systemic inflammatory dose-limiting toxicities associated with pure GSPT1 degradation (Uy 2019)[1].
BTX-1188 potently inhibits tumor cell proliferation and tumor growth in ex vivo and in vivo models of acute myeloid leukemia (AML) and in in vitro and in vivo models of lung, breast and ovarian cancer.
These preclinical results support the ongoing Phase 1 clinical evaluation of BTX-1188 in patients with AML and certain solid tumors, especially in MYC-dependent cancers.
Details for the BTX-1188 ASCO (Free ASCO Whitepaper) 2022 poster presentation are as follows:

Title: BTX-1188, a first-in-class dual degrader of GSPT1 and IKZF1/3, for treatment of acute myeloid leukemia (AML) and solid tumors
Presenter: Aparajita Hoskote Chourasia, Ph.D.
Abstract Number: 7025
Poster Number: 256
Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Date and Time: Saturday, June 4, 2022 at 9:00 a.m. CT (10:00 a.m. ET)

This poster presentation will be available on the ASCO (Free ASCO Whitepaper) Meeting website. Following the presentation at the meeting, a PDF copy of the poster will be available in the "Publications and Presentations" section of Biotheryx’s website.

About BTX-1188

Biotheryx’s lead molecular glue drug candidate BTX-1188 is a dual protein degrader which was designed to degrade GSPT1, a promising cancer target, and IKZF1/3 (also known as Ikaros/Aiolos), both clinically validated anti-inflammatory and immunomodulatory targets. Prior literature has demonstrated that degradation of GSPT1 can result in antitumor activity in difficult-to-treat tumors such as acute myeloid leukemia (AML) and in solid tumors, including those that overexpress oncogenic transcription factors, such as MYC, however, prior clinical research by others has shown that administration of a GSPT1-only degrader was associated with dose-limiting toxicities related to the release of pro-inflammatory cytokines. BTX-1188 was specifically designed as a potent degrader of GSPT1 that can also directly block inflammation by degrading IKZF1/3. In preclinical studies conducted by Biotheryx, administration of BTX-1188 led to complete eradication of tumors and extended survival in xenograft models of AML. BTX-1188 also led to potent cell killing in a number of cell lines derived from solid tumors. BTX-1188 is currently being evaluated in a Phase 1 dose-escalation trial in patients with hematologic and solid tumor malignancies.

On May 26, 2022 Delfi Diagnostics, a pioneering developer of a new class of high-performance, affordable liquid biopsy tests for early cancer detection, reported that it will present updates at the 2022 annual meeting of the American Society for Clinical Oncology (ASCO) (Free ASCO Whitepaper) in Chicago June 3-7 describing multiple applications for its next-generation liquid biopsy platform (Press release, Delfi Diagnostics, MAY 26, 2022, View Source [SID1234615138]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Delfi has made incredible progress on our screening program over the past year. Additionally, we have identified several new potential applications for our technology that we are continuing to explore," said Victor Velculescu, MD, PhD, Delfi’s founder and CEO. "We are excited to share these updates with ASCO (Free ASCO Whitepaper)’s members as we pursue multiple applications on the Delfi platform."

Delfi will present a trial-in-progress update on DELFI-L101, a prospective, case-control study to train and test classifiers for lung cancer detection. Additionally, it will present data showing that Delfi’s Tumor Fraction score, DELFI-TFTM, strongly correlates with mutant allele frequency and could serve as a useful tool to monitor tumor burden in patients with advanced cancer.